Drug: DesOwen

DesOwen® (desonide cream, ointment and lotion) Cream 0.05%, Ointment 0.05%, and Lotion 0.05% contain desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy- 16,17-[(1-methylethylidene)bis(oxy)]-,(11 β ,16 α )- a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as antiinflammatory and anti-pruritic agents. Chemically, desonide is C24H32O6. It has the following structural formula: Desonide has the molecular weight of 416.51. It is a white to off white odorless powder which is soluble in methanol and practically insoluble in water. Each gram of DesOwen® (desonide cream, ointment and lotion) Cream contains 0.5 mg of desonide in a base of citric acid, emulsifying wax, isopropyl palmitate, polysorbate 60, potassium sorbate, propyl gallate, propylene glycol, purified water, sodium hydroxide, sorbic acid, stearic acid, and synthetic beeswax. Each gram of DesOwen® (desonide cream, ointment and lotion) Ointment contains 0.5 mg of desonide in a base of mineral oil and polyethylene. Each gram of DesOwen® (desonide cream, ointment and lotion) Lotion contains 0.5 mg of desonide in a base of cetyl alcohol, edetate sodium, glyceryl stearate SE, light mineral oil, methylparaben, propylene glycol, propylparaben, purified water, sodium lauryl sulfate, sorbitan monostearate, and stearyl alcohol. May contain citric acid and/or sodium hydroxide for pH adjustment.

Source: http://www.rxlist.com

In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide was approximately 8%. These were: stinging and burning approximately 3%, irritation, contact dermatitis, condition worsened, peeling of skin, itching, intense transient erythema, and dryness/scaliness, each less than 2%. The following additional local adverse reactions have been reported infrequently with other topical corticosteroids, and they may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, secondary infection, skin atrophy, striae, and miliaria. Read the DesOwen (desonide cream, ointment and lotion) Side Effects Center for a complete guide to possible side effectsLearn More »

Source: http://www.rxlist.com

DesOwen® (desonide cream, ointment and lotion) Cream, Ointment or Lotion should be applied to the affected areas as a thin film two or three times daily depending on the severity of the condition. SHAKE LOTION WELL BEFORE USING. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. DesOwen® (desonide cream, ointment and lotion) Cream, Ointment and Lotion should not be used with occlusive dressings.

Source: http://www.rxlist.com

No information provided. Last reviewed on RxList: 8/11/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

DesOwen® (desonide cream, ointment and lotion) Cream, Ointment and Lotion are low to medium potency corticosteroids indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Source: http://www.rxlist.com

DesOwen® (desonide cream, ointment and lotion) Cream, Ointment and Lotion are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations. Last reviewed on RxList: 8/11/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Topically applied DesOwen® (desonide cream, ointment and lotion) (desonide cream, ointment and lotion) Cream, Ointment and Lotion can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS).

Source: http://www.rxlist.com

DesOwen® (desonide cream, ointment and lotion) (desonide cream) Cream 0.05% is supplied as follows: 60 g tube - NDC 0299-5770-60
60 g tube with complimentary 1 fl oz Cetaphil® Moisturizing Lotion - NDC 0299-5770-01 DesOwen® (desonide cream, ointment and lotion) (desonide ointment) Ointment 0.05% is supplied as follows: 60 g tube - NDC 0299-5775-60
60 g tube with complimentary 1 fl oz Cetaphil® Moisturizing Lotion - NDC 0299-5775-01 DesOwen® (desonide cream, ointment and lotion) (desonide lotion) Lotion 0.05% is supplied as follows: 2 fl oz bottle - NDC 0299-5765-02
2 fl oz bottle with complimentary .5 oz Cetaphil® Moisturizing Cream - NDC 0299-5765-00
4 fl oz bottle - NDC 0299-5765-04
4 fl oz bottle with complimentary .5 oz Cetaphil® Moisturizing Cream - NDC 0299-5765-03 Storage Conditions: Store between 2° and 30°C (36° and 86°F). Marketed by: GALDERMA LABORATORIES, L.P. Fort Worth, Texas 76177, USA. Mfd. by: DPT Laboratories, Ltd. San Antonio, Texas 78215, USA. Revised: June 2008. FDA Rev date: 06/12/98 Last reviewed on RxList: 8/11/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

General: Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment. Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving superpotent corticosteroids should not be treated for more than 2 weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA axis suppression. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products. Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. (See PRECAUTIONS - Pediatric use). If irritation develops, DesOwen® (desonide cream, ointment and lotion) Cream, Ointment or Lotion should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing. If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of DesOwen® (desonide cream, ointment and lotion) Cream, Ointment or Lotion should be discontinued until the infection has been adequately controlled. Laboratory tests: The following tests may be helpful in evaluating patients for HPA axis suppression: ACTH stimulation test
A.M. plasma cortisol test
Urinary free cortisol test Carcinogenesis, mutagenesis, and impairment of fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on reproduction with the use of DesOwen® (desonide cream, ointment and lotion) Cream, Ointment, and Lotion. Pregnancy:Teratogenic effects: Pregnancy category C: Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Animal reproduction studies have not been conducted with DesOwen® (desonide cream, ointment and lotion) Cream, Ointment or Lotion. It is also not known whether DesOwen® (desonide cream, ointment and lotion) Cream, Ointment or Lotion can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. DesOwen® (desonide cream, ointment and lotion) Cream, Ointment and Lotion should be given to a pregnant woman only if clearly needed. Nursing mothers: Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when DesOwen® (desonide cream, ointment and lotion) Cream, Ointment or Lotion is administered to a nursing woman. Pediatric use: Safety and effectiveness in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression when they are treated with topical corticosteroids. They are therefore also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of Cushing's syndrome while on treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children. HPA axis suppression, Cushing's syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.Last reviewed on RxList: 8/11/2008
This monograph has been modified to include the generic and brand name in many instances.

Source: http://www.rxlist.com

Health Services in

Drug Database Online

Welcome to Senior Healthcare Matters an online drug guide and dictionary, here you can get drug information and definitaions for most popular pharmaceutical and medicinal drugs, and specifically DesOwen. Find what medications you are taking today.